Like some other researchers, we have found that IDH mutations were more frequently observed in patients with intermediate risk cytogenetics (8/10, 80%) (p=0.020) and are particularly frequent in CN-AML (Cancer Genome Atlas Research Network et al., 2013; Aref et al., 2015). This evidence concerns the gene IDH1 and acute myeloid leukemia.